New paradigm for prevention of cervical cancer

European Journal of Obstetrics and Gynecology and Reproductive Biology

Volumn 130, Issue 1, 2007, Pages 25-29

  Kaufmann, Andreas M ^a   Schneider, Achim ^a  

^a Department of Gynecology ^*  (Germany)

Author keywords

Clinical studies; Human papillomavirus; Prophylactic vaccination; Virus like particles

Indexed keywords

WART VIRUS VACCINE;

CANCER IMMUNIZATION; CANCER PREVENTION; CONDYLOMA; DEVELOPING COUNTRY; EDITORIAL; FEMALE; HUMAN; PERSISTENT VIRUS INFECTION; PRECANCER; PRIORITY JOURNAL; SEXUALLY TRANSMITTED DISEASE; UNSPECIFIED SIDE EFFECT; UTERINE CERVIX CANCER; UTERINE CERVIX DYSPLASIA; VIRUS LIKE AGENT; WART VIRUS;

EID: 33845526392     PISSN: 03012115     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejogrb.2006.07.048     Document Type: Editorial

References (25)

1. Zur Hausen H. Human papillomaviruses and their possible role in squamous cell carcinomas. Curr Top Microbiol Immunol 78 (1977) 1-30
2. Gissmann L., Wolnik L., Ikenberg H., Koldovsky U., Schnurch H.G., and zur Hausen H. Human papillomavirus types 6 and 11 DNA sequences in genital and laryngeal papillomas and in some cervical cancers. Proc Natl Acad Sci USA 80 (1983) 560-563
3. Durst M., Gissmann L., Ikenberg H., and zur Hausen H. A papillomavirus DNA from a cervical carcinoma and its prevalence in cancer biopsy samples from different geographic regions. Proc Natl Acad Sci USA 80 (1983) 3812-3815
4. Walboomers J.M., Jacobs M.V., Manos M.M., et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189 (1999) 12-19
5. Parkin D.M., Bray F., Ferlay J., and Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 55 (2005) 74-108
6. Harper D.M., Franco E.L., Wheeler C., et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 364 (2004) 1757-1765
7. Villa L.L., Costa R.L., Petta C.A., et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 6 (2005) 271-278
8. Harper D.M., Franco E.L., Wheeler C.M., et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 367 9518 (2006) 1247-1255
9. Boland G., Beran J., Lievens M., et al. Safety and immunogenicity profile of an experimental hepatitis B vaccine adjuvanted with AS04. Vaccine 23 (2004) 316-320
10. Mao C., Koutsky L.A., Ault K.A., et al. Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol 107 (2006) 18-27
11. Viscidi R.P., Snyder B., Cu-Uvin S., et al. Human papillomavirus capsid antibody response to natural infection and risk of subsequent HPV infection in HIV-positive and HIV-negative women. Cancer Epidemiol Biomarkers Prev 14 (2004) 283-288
12. Center for Disease Control and Prevention. Poliomyelitis prevention in the United States: updated recommendation of the advisory committee on immunization practices (ACIP). MMWR Morb Mortal Wkly Rep 49 RR-5 (2000) 1-22
13. Koutsky L.A., Ault K.A., Wheeler C.M., et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 347 (2002) 1645-1651
14. Castle P.E., Solomon D., Schiffman M., and Wheeler C.M. Human papillomavirus type 16 infections and 2-year absolute risk of cervical precancer in women with equivocal or mild cytologic abnormalities. J Natl Cancer Inst 97 (2005) 1066-1071
15. Khan M.J., Castle P.E., Lorincz A.T., et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst 97 (2005) 1072-1079
16. Schneider A., Bernard L., Schwarz T.F., Hammerschmidt T., and Siebert U. Impact of vaccination with a HPV-16/18 vaccine on invasive cervical cancer incidence and mortality in Germany: a model-based analysis. EUROGIN. Paris, France (2006) [abstract SS 20-5]
17. Ferris D.G. Clinical efficacy in HPV positive women: widening the benefit. EUROGIN. Paris, France (2006) [abstract S 11-2]
18. Olsson S.E. EUROGIN. Paris, France. Post-infection prophylaxis of a quadrivalent HPV (types 6, 11, 16, 18) L1 VLP vaccine: a combined analysis (2006) [abstract SS 8-2]
19. Hughes J.P., Garnett G.P., and Koutsky L.A. The theoretical population-level impact of a prophylactic human papillomavirus vaccine. Epidemiology 13 (2002) 631-639
20. Garnett G.P. Role of herd immunity in determining the effect of vaccines against sexually transmitted disease. J Infect Dis 191 Suppl. 1 (2005) S97-S106
21. Taira A.V. Evaluating human papillomavirus vaccination programs. Emerg Infect Dis 10 (2004) 1915-1923
22. Zimmerman R.K. Ethical analysis of HPV vaccine policy options. Vaccine 24 22 (2006) 4812-4820
23. Frazer I.H., Cox J.T., Mayeaux Jr. E.J., et al. Advances in prevention of cervical cancer and other human papillomavirus-related diseases. Pediatr Infect Dis J 25 2 Suppl. (2006) S65-S81 quiz S82
24. Klug S.J., Hetzer M., and Blettner M. Screening for breast and cervical cancer in a large German city: participation, motivation and knowledge of risk factors. Eur J Public Health 15 (2005) 70-77
25. Koutsky L. Epidemiology of genital human papillomavirus infection. Am J Med 102 (1997) 3-8